International journal of hematology · 2006
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamaguchi Masaki, Kotani Takeharu, Nakamura Yoshihisa, Ueda Mikio
Аннотация
We report a case of refractory peripheral T-cell lymphoma (PTCL) successfully treated with a combination of fludarabine and cyclophosphamide (FLU/CY). A 68-year-old man with concurrent PTCL and diffuse large B-cell lymphoma was treated effectively with 3-course CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy, but PTCL relapse occurred and was resistant to ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) therapy. FLU/CY therapy led to complete remission, which was maintained for almost 14 months after a single course. We concluded that a FLU/CY regimen may be useful for attaining long-term remission in patients with refractory relapsed PTCL and should therefore be considered a valuable treatment choice.
Предметные рубрики MeSH
AgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinCyclophosphamideCytarabineDoxorubicinDrug Resistance, NeoplasmEtoposideHumansLymphoma, B-CellLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell, PeripheralMaleMethylprednisoloneNeoplasms, Second PrimaryPrednisoneRecurrenceRemission InductionTime FactorsVidarabineVincristine